Humans ; Syndrome ; Vestibular Aqueduct ; Vestibular Diseases

Ear Diseases ; Ear, Middle ; Humans ; Sclerosis

0.05).The sera from animals immunized with parental strains had significant higher titer of IgG antibodies against GM1,GD1a and GT1b,at 14 and 28 day than before immunization(P

Objective To evaluate the experience in the diagnosis and surgical treatment of primary retroperitoneal tumor (PRT). Methods Clinical data of PRT 63 cases from January 1990 to March 2007 confirmed by pathology were retrospectively analyzed including clinical manifestation, surgical procedures, pathological examination and follow-up. Results Tumors were benign in 25 patients and malignant in 38. The main symptoms and signs were abdominal mass. The Youdon's index of CT examination for distinguishing benign from malignant tumors was 85%. The complete surgical resection rate was 88% for benign tumors and 68% for malignances. Removal of the involved organs or vessels was needed in 40% patients in complete surgical resection group. Postoperative recurrence was high in those the tumor was not completely removed and those the tumor was malignant. The 5-year survival rate for complete surgical resection of benign tumors was 83.6% ,and that of malignant tumors was 27.3%. After a median follow-up of 36 months (range 5 ～ 168)for the resection of malignant tumors, the local recurrence rate was 53%. Median time between initial surgery and recurrence was 25 months (range 3 ～ 108). For local recurrence of malignant tumor, the complete surgical resection rate was 62.5%. One patient died of intraabdominal hemorrhage in the first day after operation. Conclusion For PRT patients, early diagnosis is often difficult. Preoperative imaging results are essential to predict the surgical resectability. The optimal treatment of patients with PRT is radical resection, an bloc organ resection if necessary. Regularly postoperative follow-up is mandatory for early finding recurrence.

AIM: To synthesize biodegradable poly lactic acid (PLA) through the optimization and selection of process and catalyst.METHODS: This experiment was performed at the Research Center for Green Chemistry and Technology in the School of Municipal and Environmental Engineering of Harbin Institute of Technology from February 2003 to October 2004. Biodegradable poly L-lactic acid (PLLA) was synthesis by melt polycondensation using L-lactic acid (LA) as material. Firstly, oligo L-lactic acid (OLLA) was prepared by dehydrating aqueous solution of LA without catalyst. And then, the mixture of OLLA and catalyst was heated at a certain temperature and pressure for a period of time to get the product of PLLA. The structure of PLLA was characterized by Fourier transform infrared (FTIR) spectra and 1H- nuclear magnetic resonance (1H-NMR) spectra. The polydispersity was determined by gel permeation chromatography (GPC).RESULTS: OLLA with the viscosity average molecular weight (Mη) of 6 500 g/mol was prepared by the following steps: the solution of LA without catalyst was dehydrated at 140 ℃, first at reduced pressure of 30 kPa for 2 hours, and then at 5 kPa for 4 hours. SnCl2-p-toluenesulfonic acid (TSA) system was the effective catalyst for the polycondensation of OLLA. After the mixture of OLLA and catalysts polycondensed at 165 ℃ and 5 kPA for about 8 hours, PLLA with the Mη of 65 000 g/mol was obtained by using SnCl2-TSA system as catalyst with the SnCl2 amount of 0.4wt% to OLLA and equal mol ratio of SnCl2 and TSA.CONCLUSION:PLLA with a certain practicability was obtained under the optimal process and catalyst. Oligomerization of LA played an important role on improving the molecular weight of PLLA.

Animals ; Genetic Therapy ; Vestibular Diseases ; therapy

Acute Disease ; Adult ; Ethylene Oxide ; poisoning ; Female ; Humans ; Male ; Middle Aged

Humans ; Tinnitus

Objective To better understand and manage the current situation and problems of patent transformation in university affiliated hospital.Methods we conducted the statistical analysis the quantity of patent authorization in the Peking University People's Hospital during 2002-2013,and the status of patent transformation.Results The quantity of patent authorization increased significantly,however the number of patent transformation is small,with low proportion.Meantime,the transformation period is long,with single mode.Conclusions the hospital should be strengthened for all patent life-cycle management,and strengthen the emphasis on the conversion work to build integrated management team,in particular by building technological achievements promotion platform,improve the incentive mechanism to strengthen the franchise use of the work.

Objectives To investigate serum levels of B cell activating factor(BAFF)in Chinese patients with polymyositis(PM)or dermatomyositis(DM),and analyze the correlation of BAFF with autoantibodies and clinical phenotypes.Methods Serum BAFF levels of 28 PM patients and 30 DM patients(study group),and 25 matched healthy controls(control group)were measured by ELISA.Serum anti-Jo-1 antibody levels were also measured by ELISA in all the subjects.The results of the two groups were compared by unpaired t test and the relevance was analyzed by Pearson's correlation analysis.Results Serum levels of BAFF in PM/DM patients were significantly higher compared to healthy controls(P =0.000),but there was no statistically significant difference between the PM and DM patients(P ＞ 0.05).Patients with interstitial lung disease(ILD)had significantly higher serum BAFF level than the patients without ILD(P =0.000)or the controls(P =0.000).Serum BAFF levels of patients with positive antinuclear antibody(ANA)were significantly higher than those with negative ANA(P =0.003).For patients with anti-Jo-1 antibodies,the serum BAFF levels were correlated with the serum concentration of anti-Jo-1 antibodies(r =0.799,P =0.006).Conclusions Serum levels of BAFF are increased in Chinese PM/DM patients.These findings indicate that BAFF may be possibly enrolled in the pathogenesis of PM/DM.Detecting serum BAFF levels could have some implication for the diagnosis and treatment of PM/DM.